X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RV-1770 is an innovative mRNA-based vaccine formulation with a unique AI-enhanced design using the sequence of the recent RSV clinical isolate. It demonstrated immunogenic responses and neutralization against both type A and B strains of RSV in preclinical cotton rat studies.
Lead Product(s): RV-1770
Therapeutic Area: Infections and Infectious Diseases Product Name: RV-1770
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Sirnaomics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
RV-1730 targets the SARS-CoV-2 variants and is being investigated as an effective vaccine booster with the potential to provide continued protection against COVID-19 infection.
Lead Product(s): RV-1730
Therapeutic Area: Infections and Infectious Diseases Product Name: RV-1730
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
RNAimmune is focusing on pan-ras mRNA vaccine which elicits specific immune responses and inhibits tumor growth in the mouse model of colon cancer prolonging survival.
Lead Product(s): mRNA-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
The proceeds of thne financing will support the company to anticipate filing an IND with the FDA in the fourth quarter of 2022 to initiate a Phase I study to evaluate the safety, tolerability, and pharmacokinetics of RIM730.
Lead Product(s): RIM730
Therapeutic Area: Infections and Infectious Diseases Product Name: RIM730
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Sirnaomics
Deal Size: $27.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 29, 2022
Details:
The Company will use the proceeds to advance its Covid-19 vaccine (RV1730) program and neoantigen-based cancer vaccine programs.
Lead Product(s): RV1730
Therapeutic Area: Infections and Infectious Diseases Product Name: RV1730
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Terra Magnum Capital Partners
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Financing August 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
